S&P 500   3,577.59 (+0.56%)
DOW   29,591.27 (+1.12%)
QQQ   290.52 (+0.05%)
AAPL   114.00 (-2.85%)
MSFT   210.12 (-0.13%)
FB   268.85 (-0.32%)
GOOGL   1,727.00 (-0.54%)
AMZN   3,097.05 (-0.08%)
TSLA   521.00 (+6.41%)
NVDA   525.00 (+0.28%)
BABA   270.30 (-0.16%)
CGC   24.72 (+4.22%)
GE   10.09 (+3.38%)
MU   64.18 (+4.53%)
AMD   85.31 (+0.79%)
T   28.60 (+0.99%)
NIO   55.64 (+12.97%)
F   8.84 (+1.14%)
ACB   7.18 (+0.70%)
GILD   59.88 (-0.38%)
NFLX   476.99 (-2.30%)
BA   211.84 (+6.12%)
DIS   145.76 (+3.32%)
S&P 500   3,577.59 (+0.56%)
DOW   29,591.27 (+1.12%)
QQQ   290.52 (+0.05%)
AAPL   114.00 (-2.85%)
MSFT   210.12 (-0.13%)
FB   268.85 (-0.32%)
GOOGL   1,727.00 (-0.54%)
AMZN   3,097.05 (-0.08%)
TSLA   521.00 (+6.41%)
NVDA   525.00 (+0.28%)
BABA   270.30 (-0.16%)
CGC   24.72 (+4.22%)
GE   10.09 (+3.38%)
MU   64.18 (+4.53%)
AMD   85.31 (+0.79%)
T   28.60 (+0.99%)
NIO   55.64 (+12.97%)
F   8.84 (+1.14%)
ACB   7.18 (+0.70%)
GILD   59.88 (-0.38%)
NFLX   476.99 (-2.30%)
BA   211.84 (+6.12%)
DIS   145.76 (+3.32%)
S&P 500   3,577.59 (+0.56%)
DOW   29,591.27 (+1.12%)
QQQ   290.52 (+0.05%)
AAPL   114.00 (-2.85%)
MSFT   210.12 (-0.13%)
FB   268.85 (-0.32%)
GOOGL   1,727.00 (-0.54%)
AMZN   3,097.05 (-0.08%)
TSLA   521.00 (+6.41%)
NVDA   525.00 (+0.28%)
BABA   270.30 (-0.16%)
CGC   24.72 (+4.22%)
GE   10.09 (+3.38%)
MU   64.18 (+4.53%)
AMD   85.31 (+0.79%)
T   28.60 (+0.99%)
NIO   55.64 (+12.97%)
F   8.84 (+1.14%)
ACB   7.18 (+0.70%)
GILD   59.88 (-0.38%)
NFLX   476.99 (-2.30%)
BA   211.84 (+6.12%)
DIS   145.76 (+3.32%)
S&P 500   3,577.59 (+0.56%)
DOW   29,591.27 (+1.12%)
QQQ   290.52 (+0.05%)
AAPL   114.00 (-2.85%)
MSFT   210.12 (-0.13%)
FB   268.85 (-0.32%)
GOOGL   1,727.00 (-0.54%)
AMZN   3,097.05 (-0.08%)
TSLA   521.00 (+6.41%)
NVDA   525.00 (+0.28%)
BABA   270.30 (-0.16%)
CGC   24.72 (+4.22%)
GE   10.09 (+3.38%)
MU   64.18 (+4.53%)
AMD   85.31 (+0.79%)
T   28.60 (+0.99%)
NIO   55.64 (+12.97%)
F   8.84 (+1.14%)
ACB   7.18 (+0.70%)
GILD   59.88 (-0.38%)
NFLX   476.99 (-2.30%)
BA   211.84 (+6.12%)
DIS   145.76 (+3.32%)
Log in
NASDAQ:MRTX

Mirati Therapeutics Stock Forecast, Price & News

$224.74
-2.15 (-0.95 %)
(As of 11/23/2020 03:59 PM ET)
Add
Compare
Today's Range
$222.64
Now: $224.74▼
$228.63
50-Day Range
$162.05
MA: $203.03▼
$236.60
52-Week Range
$66.01
Now: $224.74▼
$240.58
Volume11,539 shs
Average Volume519,294 shs
Market Capitalization$11.30 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.85
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and sitravatinib, a spectrum-selective kinase inhibitor that is in Phase II clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and a clinical collaboration agreement with Novartis Pharmaceuticals Corporation. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
Read More
Mirati Therapeutics logo

Beat the Market (BTM) Rank™

Analyst Opinion: 2.3Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.04 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MRTX
Previous Symbol
CUSIPN/A
CIK1576263
Webwww.mirati.com
Phone858-332-3410
Employees111

Debt

Debt-to-Equity RatioN/A
Current Ratio11.34
Quick Ratio11.34

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$3.34 million
Price / Sales3,383.28
Cash FlowN/A
Price / Cash FlowN/A
Book Value$9.67 per share
Price / Book23.24

Profitability

EPS (Most Recent Fiscal Year)($5.69)
Net Income$-213,260,000.00
Net Margins-10,983.84%
Return on Equity-60.10%
Return on Assets-54.58%

Miscellaneous

Outstanding Shares50,281,000
Market Cap$11.30 billion
Next Earnings Date2/23/2021 (Estimated)
OptionableOptionable
$224.74
-2.15 (-0.95 %)
(As of 11/23/2020 03:59 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for MRTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Mirati Therapeutics (NASDAQ:MRTX) Frequently Asked Questions

How has Mirati Therapeutics' stock price been impacted by COVID-19?

Mirati Therapeutics' stock was trading at $77.37 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MRTX shares have increased by 190.5% and is now trading at $224.74.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Mirati Therapeutics?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last year. There are currently 1 sell rating, 4 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Mirati Therapeutics.

What stocks does MarketBeat like better than Mirati Therapeutics?

Wall Street analysts have given Mirati Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Mirati Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Mirati Therapeutics' next earnings date?

Mirati Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, February 23rd 2021.
View our earnings forecast for Mirati Therapeutics.

How were Mirati Therapeutics' earnings last quarter?

Mirati Therapeutics, Inc. (NASDAQ:MRTX) released its quarterly earnings data on Wednesday, November, 4th. The biotechnology company reported ($1.96) EPS for the quarter, beating analysts' consensus estimates of ($2.03) by $0.07. The biotechnology company had revenue of $11.40 million for the quarter, compared to analysts' expectations of $0.21 million. Mirati Therapeutics had a negative return on equity of 60.10% and a negative net margin of 10,983.84%. The business's revenue was up 1053.8% on a year-over-year basis.
View Mirati Therapeutics' earnings history.

What price target have analysts set for MRTX?

15 Wall Street analysts have issued twelve-month price targets for Mirati Therapeutics' shares. Their forecasts range from $116.00 to $267.00. On average, they anticipate Mirati Therapeutics' stock price to reach $215.36 in the next year. This suggests that the stock has a possible downside of 4.2%.
View analysts' price targets for Mirati Therapeutics.

Are investors shorting Mirati Therapeutics?

Mirati Therapeutics saw a decline in short interest during the month of October. As of October 30th, there was short interest totaling 3,740,000 shares, a decline of 13.6% from the October 15th total of 4,330,000 shares. Based on an average daily trading volume, of 522,400 shares, the days-to-cover ratio is presently 7.2 days.
View Mirati Therapeutics' Short Interest.

Who are some of Mirati Therapeutics' key competitors?

Some companies that are related to Mirati Therapeutics include Astellas Pharma (ALPMY), Shiseido (SSDOY), Takeda Pharmaceutical (TKPYY), Alexion Pharmaceuticals (ALXN), BeiGene (BGNE), Royalty Pharma (RPRX), Genmab A/S (GMAB), Genmab A/S (GNMSF), UCB (UCBJF), MERCK Kommanditgesellschaft auf Aktien (MKGAF), Catalent (CTLT), Ono Pharmaceutical (OPHLF), Horizon Therapeutics Public (HZNP), Alnylam Pharmaceuticals (ALNY) and CureVac (CVAC).
View all competitors.

What other stocks do shareholders of Mirati Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirati Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), QUALCOMM (QCOM), BioMarin Pharmaceutical (BMRN), Micron Technology (MU), Netflix (NFLX), Square (SQ), Alibaba Group (BABA) and DocuSign (DOCU).

Who are Mirati Therapeutics' key executives?

Mirati Therapeutics' management team includes the following people:
  • Dr. Charles M. Baum, Pres, CEO & Director (Age 62, Pay $1.01M)
  • Dr. James G. Christensen, Chief Scientific Officer & Exec. VP (Age 52, Pay $655k)
  • Mr. Daniel R. Faga, Exec. VP, COO & Principal Financial Officer (Age 40)
  • Ms. Vickie S. Reed, Sr. VP of Technical Operation & Chief Accounting Officer (Age 58)
  • Temre Johnson, Director of Investor Relations & Corp. Communications
  • Ms. Reena R. Desai, VP, Gen. Counsel & Corp. Sec.
  • Dr. Matthew Marx Ph.D., Sr. VP & Head of Drug Discovery
  • Mr. Philip Roberts, Sr. VP of Technical Operations
  • Mr. Benjamin J. Hickey, Exec. VP & Chief Commercial Officer (Age 45)
  • Dr. Kelly Covello Ph.D., VP & Head of Medical Affairs

What is Mirati Therapeutics' stock symbol?

Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."

Who are Mirati Therapeutics' major shareholders?

Mirati Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (6.83%), BlackRock Inc. (7.66%), Sands Capital Management LLC (2.65%), State Street Corp (2.16%), UBS Asset Management Americas Inc. (1.29%) and EcoR1 Capital LLC (0.92%). Company insiders that own Mirati Therapeutics stock include Aaron I Davis, Avoro Capital Advisors Llc, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Christopher C Lemasters, Craig A Johnson, Henry J Fuchs, Isan Chen, Jamie A Donadio, Ltd Braslyn, Michael G Grey and Venbio Select Advisor Llc.
View institutional ownership trends for Mirati Therapeutics.

Which institutional investors are selling Mirati Therapeutics stock?

MRTX stock was sold by a variety of institutional investors in the last quarter, including Sands Capital Management LLC, Lord Abbett & CO. LLC, State Street Corp, Clough Capital Partners L P, Sphera Funds Management LTD., BlackRock Inc., Polar Capital LLP, and Polar Capital LLP. Company insiders that have sold Mirati Therapeutics company stock in the last year include Boxer Capital, Llc, Charles M Baum, Craig A Johnson, Henry J Fuchs, Isan Chen, and Ltd Braslyn.
View insider buying and selling activity for Mirati Therapeutics.

Which institutional investors are buying Mirati Therapeutics stock?

MRTX stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Wells Fargo & Company MN, EcoR1 Capital LLC, Charles Schwab Investment Management Inc., UBS Asset Management Americas Inc., Federated Hermes Inc., Handelsbanken Fonder AB, and Assenagon Asset Management S.A..
View insider buying and selling activity for Mirati Therapeutics.

How do I buy shares of Mirati Therapeutics?

Shares of MRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Mirati Therapeutics' stock price today?

One share of MRTX stock can currently be purchased for approximately $224.74.

How big of a company is Mirati Therapeutics?

Mirati Therapeutics has a market capitalization of $11.30 billion and generates $3.34 million in revenue each year. The biotechnology company earns $-213,260,000.00 in net income (profit) each year or ($5.69) on an earnings per share basis. Mirati Therapeutics employs 111 workers across the globe.

What is Mirati Therapeutics' official website?

The official website for Mirati Therapeutics is www.mirati.com.

How can I contact Mirati Therapeutics?

Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-332-3410 or via email at [email protected]

This page was last updated on 11/23/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.